Patent · US Active

MLKL inhibitors

US11666577B2 · kind B2 · utility

0Cited by

1References

20Claims

0Family size

Assignee

National Institute of Biological Sciences, Beijing · CN

Inventors

Zhiyuan Zhang · Beijing, CN
Xiaodong Wang · Zhejiang, CN
Shaoqiang Huang · Beijing, CN
Bo Yan · Shanghai, CN
Lei Liu · Thousand Oaks, US
Huayi Wang · Beijing, CN
Jianguang Han · Beijing, CN
Zhi Cong Huang · Nanhu, CN
Weiye Cao · Beijing, CN

Key dates

Filing date	Aug 26, 2019
Grant date	Jun 6, 2023
Priority date	—
Expiry date	Mar 11, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/5377
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides compounds that inhibit human MLKL, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.